Full Press Release Details
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers.
ARGX
arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
Key Takeaway: arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis